Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered from Stroke

Medicine (United States)

Volumn 95, Issue 15, 2016, Pages

  Wang, Wei Ting ^a   You, Li Kai ^a   Chiang, Chern En ^a   Sung, Shih Hsien ^a,b,c   Chuang, Shao Yuan ^d   Cheng, Hao Min ^a,b,c   Chen, Chen Huan ^a,b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Institute of Public Health   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ARTICLE; BAYESIAN LEARNING; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; HEART DISEASE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENT; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REGRESSION ANALYSIS; SYSTEMATIC REVIEW; CLASSIFICATION; COMPLICATION; PROCEDURES; SECONDARY PREVENTION; STROKE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; SECONDARY PREVENTION; STROKE;

EID: 84964618027     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003302     Document Type: Article

References (44)

1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6:182-187.
2. Organization, W.H., UNAIDS. Prevention of Cardiovascular Disease. Geneva, Switzerland: World Health Organization; 2007.
3. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTER-STROKE study): a case-control study. Lancet. 2010;376:112-123.
4. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34:2741-2748.
5. Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group. JAMA. 1974;229:409-418.
6. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.
7. McCarthy M. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clinical research ed). 1986;293:1570.
8. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255-3264.
9. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
10. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group. Stroke. 1993;24:543-548.
11. Eriksson S, Olofsson B, Wester P. Atenolol in secondary prevention after stroke. Cerebrovasc Dis. 1995;5:21-25.
12. Group PC. Post-stroke antihypertensive treatment study. A preliminary result. Chinese Med J. 1995;108:710-717.
13. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Anti-hypertensive intervention trials) Project Collaborators. Stroke. 1997;28:2557-2562.
14. Pantoni L, Bianchi C, Beneke M, et al. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 2000;175:116-123.
15. Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358:2130-2131.
16. Group PC. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
17. Group PC. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J. 2003;24:475-484.
18. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226.
19. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-1237.
20. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
21. Trenkwalder P, Elmfeldt D, Hofman A, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): major CV events and stroke in subgroups of patients. Blood Press. 2005;14:31-37.
22. Liu LS, Gong LS, Wang W. Blood Pressure Lowering to Prevent Recurrent Stroke Study G. Effects of blood pressure lowering treatment on stroke recurrence in patients with cerebrovascular diseases: a large-scale, randomized, placebo controlled trial. Zhon-ghua Xin Xue Guan Bing Za Zhi. 2005;33:613-617.
23. Liao JK. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation. 2007;115:1615-1621.
24. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
25. Krause T, Lovibond K, Caulfield M, et al., Guideline Development G. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.
26. Chiang CE, Wang TD, Ueng KC, et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc. 2015;78:1-47.
27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
28. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236.
29. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
30. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
31. Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032-1040.
32. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607-617.
33. Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Phys. 2013;16:E705-E714.
34. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analy-sis: an overview and tutorial. J Clin Epidemiol. 2011;64:163-171.
35. Lu G, Ades A. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101:447-459.
36. Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008.
37. Borenstein M, Hedges L, Higgins J, et al. Comprehensive Meta-analysis Version 2. Englewood, NJ: Biostat; 2005.
38. Chaffman M, Heel R C, Brogden R N, et al. Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1984;28:189-235.
39. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature. 1999;399(6738 Suppl): A7-14.
40. Kono Y, Yamada S, Kamisaka K, et al. Recurrence risk after noncardioembolic mild ischemic stroke in a Japanese population. Cerebrovasc Dis (Basel, Switzerland). 2011;31:365-372.
41. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
42. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflu-methiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366: 895-906.
43. Eriksson S, Olofsson B-O, Wester P-O. Atenolol in secondary prevention after stroke. Cerebrovasc Dis. 1995;5:21-25.
44. Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358:2130-2131.